Aspira Women’s Health Announces Publication of Two OvaWatch Peer-Reviewed Manuscripts
07 Maio 2024 - 9:00AM
Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq:
AWH), a bio-analytical based women’s health company focused on the
development of gynecologic disease diagnostic tools, today
announced the publication of two peer-reviewed manuscripts.
The first manuscript, entitled “Ovarian Cancer Surgical
Consideration is Markedly Improved by the Neural Network
Powered-MIA3G Multivariate Index Assay” was published in the
peer-reviewed journal Frontiers of Medicine on May 2, 2024. The
findings of this study demonstrate that use of OvaWatch® to
stratify risk in patients with an adnexal mass might help to reduce
surgical backlogs and unnecessary surgical referrals.
The second manuscript, entitled: “Neural Network-derived
Multivariate Index Assay Demonstrates Effective Clinical
Performance in Longitudinal Monitoring of Ovarian Cancer Risk” was
published in the journal Gynecologic Oncology on May 3, 2024. The
findings of this study demonstrate that OvaWatch could be an
effective tool for the monitoring of ovarian cancer risk over time
in women with indeterminate or low risk adnexal masses. Based on
common practice for adnexal mass management and consistent with the
study, OvaWatch can be drawn by the provider every three to six
months for active surveillance of an adnexal mass.
“Today, we mark the publication of additional clinical data to
support the use of OvaWatch for the assessment of ovarian cancer
risk for women with an adnexal mass,” said Nicole Sandford, Chief
Executive Officer of Aspira. “We believe these studies will help
accelerate the adoption of OvaWatch for initial and ongoing
monitoring of patients to provide an alternative to surgical
intervention for lower risk cases. Clinicians have long sought a
better tool to develop an appropriate care plan for these women,
and OvaWatch provides it.”
“The publication of these manuscripts, along with last week’s
announcement to make OvaWatch available for testing over time, is
the latest example of Aspira keeping its promises to our
stakeholders. We are well on our way to achieving our mission to
improve outcomes for women with gynecologic diseases.”
The total addressable market for OvaSuite, the company’s
portfolio of ovarian cancer risk assessment blood tests, is 2.0-3.0
million tests per year.
About Aspira Women’s Health Inc.Aspira Women’s
Health Inc. is dedicated to the discovery, development, and
commercialization of noninvasive, AI-powered tests to aid in the
diagnosis of gynecologic diseases.
OvaWatch® and Ova1Plus® are offered to clinicians as OvaSuiteSM.
Together, they provide the only comprehensive portfolio of blood
tests to aid in the detection of ovarian cancer for the 1.2+
million American women diagnosed with an adnexal mass each year.
OvaWatch provides a negative predictive value of 99% and is used to
assess ovarian cancer risk for women where initial clinical
assessment indicates the mass is indeterminate or benign, and thus
surgery may be premature or unnecessary. Ova1Plus is a reflex
process of two FDA-cleared tests, Ova1® and Overa®, to assess the
risk of ovarian malignancy in women planned for surgery.
Our in-development test pipeline is designed to expand our
ovarian cancer portfolio and addresses the tremendous need for
noninvasive diagnostics for endometriosis, a debilitating disease
that impacts millions of women worldwide. In ovarian cancer, our
OvaMDxSM risk assessment is designed to combine microRNA and
protein biomarkers with patient data to further enhance the
sensitivity and specificity of our current tests. In endometriosis,
EndoCheckSM is the first-ever noninvasive test designed to identify
endometriomas, one of the most commonly occurring forms of
endometriosis. The EndoMDxSM test is designed to combine microRNA
and protein biomarkers with patient data to identify all
endometriosis.
Forward-Looking StatementsThis press release
contains forward-looking statements, as defined in the Private
Securities Litigation Reform Act of 1995. Forward-looking
statements involve a number of risks and uncertainties. Such
forward-looking statements include statements regarding, among
other things, the timing and completion of any products in the
pipeline development and other statements that are predictive in
nature. Actual results could differ materially from those discussed
due to known and unknown risks, uncertainties, and other factors.
These forward-looking statements generally can be identified by the
use of words such as “designed to,” “expect,” “plan,” “anticipate,”
“could,” “may,” “intend,” “will,” “continue,” “future,” other words
of similar meaning and the use of future dates. Forward-looking
statements in this press release and other factors that may cause
such differences include the satisfaction of customary closing
conditions related to the offering and the expected timing of the
closing of the offering. These and additional risks and
uncertainties are described more fully in the company’s filings
with the SEC, including those factors identified as “Risk Factors”
in our most recent Annual Report on Form 10-K, for the fiscal year
ended December 31, 2023. If any of these risks materialize or our
assumptions prove incorrect, actual results could differ materially
from the results implied by these forward-looking statements. There
may be additional risks that Aspira presently does not know, or
that Aspira currently believes are immaterial, that could also
cause actual results to differ from those contained in the
forward-looking statements. In addition, forward-looking statements
reflect Aspira’s expectations, plans, or forecasts of future events
and views as of the date of this press release. Subsequent events
and developments may cause the Company’s assessments to change.
However, while Aspira may elect to update these forward-looking
statements at some point in the future, Aspira expressly disclaims
any obligation to do so, except as required by law. These
forward-looking statements should not be relied upon as
representing Aspira’s assessments of any date after the date of
this press release. Accordingly, undue reliance should not be
placed upon the forward-looking statements.
Investor Relations Contact: Torsten
Hombeck, Ph.D. Chief Financial Officer Aspira Women’s
Health Investors@aspirawh.com
Aspira Womans Health (NASDAQ:AWH)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Aspira Womans Health (NASDAQ:AWH)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024